FDA Drug Shortages

Current and Resolved Drug Shortages and Discontinuations Reported to FDA

Start Over | Back to Previous Screen

Hydralazine Hydrochloride Injection, USP
Status: Currently in Shortage
»Date first posted: 09/08/2020
»Therapeutic Categories: Cardiovascular

Expand all

Akorn Pharmaceuticals (New 09/08/2020)

Company Contact Information:
800-932-5676

Presentation Availability and Estimated Shortage Duration Related Information Shortage Reason (per FDASIA)
20 mg/mL, 1mL single dose vial (box of 10) (NDC 17478-934-01) Not available Not available Other
20 mg/mL, 1mL single dose vial (box of 25) (NDC 17478-934-15) Limit availability / Recovery expected Oct 2020 Manufacturer interruption production issues. Other

Fresenius Kabi USA, LLC (Revised 10/23/2020)

Company Contact Information:
888-386-1300

Presentation Availability and Estimated Shortage Duration Related Information Shortage Reason (per FDASIA)
20 mg per mL, SDV (NDC 63323-614-01) Backordered. Next release expected November 2020. Check wholesaler for inventory Manufacturing Delay

Mylan Institutional (Reverified 10/14/2020)

Company Contact Information:
800-796-9526

Presentation Availability and Estimated Shortage Duration Related Information Shortage Reason (per FDASIA)
20 mg / 1 ml] 25PK (NDC 67457-291-01) Intermittent supply Demand increase for the drug

X-GEN Pharmaceuticals, Inc. (Revised 09/09/2020)

Company Contact Information:
866-390-4411

Presentation Availability and Estimated Shortage Duration Related Information Shortage Reason (per FDASIA)
20 mg/mL per vial (NDC 39822-0500-4) Not available and no plans to manufacture at this time. Other

Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Language Assistance Available: Español | 繁體中文 | Tiếng Việt | 한국어 | Tagalog | Русский | العربية | Kreyòl Ayisyen | Français | Polski | Português | Italiano | Deutsch | 日本語 | فارسی | English